电邮这篇文章 The Search for Pharmacologically Active Compounds Among the 2-Dialkylaminobenzimidazoles
- 作者: Zhukovskaya O.N.1, Anisimova V.A.1, Spasov A.A.2,3, Yakovlev D.S.2,3, Gurova N.A.2, Kucheryavenko A.F.2, Salaznikova O.A.2, Kuznetsova V.A.2,3, Mal’tsev D.V.2,3, Brigadirova A.A.2,3, Morkovina Y.V.3, Solov’eva O.A.2, Gurova V.V.2, Reznikov E.V.2
-
隶属关系:
- Science Research Institute of Physical and Organic Chemistry, Southern Federal University
- Volgograd State Medical University, Ministry of Health of the Russian Federation
- Volgograd Medical Scientific Center
- 期: 卷 51, 编号 3 (2017)
- 页面: 182-186
- 栏目: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/244525
- DOI: https://doi.org/10.1007/s11094-017-1578-3
- ID: 244525
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
订阅存取
详细
Heating of substituted benzimidazole-2-sulfonic acids in the presence of excess quantities of secondary amines was used to synthesize dialkylaminobenzimidazoles. Experimental studies of potential antiarrhythmic, antiaggregation, hemorheological, AT1 angiotensin- and NHE-1-inhibiting, and antiserotonin activity identified active compounds. 1[-2-(5-Methyl)benzimidazole]pyrrolidine had greater NHE-inhibiting activity than zoniporide. 1-{[2-(5-Methoxy)benzimidazole]-4-N-methyl}piperazine dihydrochloride had greater antiaggregatory activity than acetylsalicylic acid, while 1-[2-(5-methyl)benzimidazole]piperidine was as active as cyproheptadine in terms of 5-HT2A antagonistic activity. 1-(2-Benzimidazole)pyrrolidine and 1-[2-(5-chloro) benzimadazole pyrrolidine dihydrochlorides had 5-HT3 antagonist activity equal to that of tropisetron..
作者简介
O. Zhukovskaya
Science Research Institute of Physical and Organic Chemistry, Southern Federal University
编辑信件的主要联系方式.
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Rostov-on-Don
V. Anisimova
Science Research Institute of Physical and Organic Chemistry, Southern Federal University
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Rostov-on-Don
A. Spasov
Volgograd State Medical University, Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd; Volgograd
D. Yakovlev
Volgograd State Medical University, Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd; Volgograd
N. Gurova
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
A. Kucheryavenko
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
O. Salaznikova
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
V. Kuznetsova
Volgograd State Medical University, Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd; Volgograd
D. Mal’tsev
Volgograd State Medical University, Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd; Volgograd
A. Brigadirova
Volgograd State Medical University, Ministry of Health of the Russian Federation; Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd; Volgograd
Ya. Morkovina
Volgograd Medical Scientific Center
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
O. Solov’eva
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
V. Gurova
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
E. Reznikov
Volgograd State Medical University, Ministry of Health of the Russian Federation
Email: zhukowskaia.ol@yandex.ru
俄罗斯联邦, Volgograd
补充文件
